ScoreWhy is PharmaBlock Sciences (Nanjing), Inc. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 17.38% and Operating profit at 4.40% over the last 5 years
2
Flat results in Jun 25
- ROCE(HY) Lowest at 5.96%
- RAW MATERIAL COST(Y) Grown by 18.09% (YoY)
- NET PROFIT(Q) At CNY 36.17 MM has Fallen at -29.7%
3
With ROE of 5.33%, it has a fair valuation with a 2.12 Price to Book Value
- Over the past year, while the stock has generated a return of 2.73%, its profits have risen by 23.2% ; the PEG ratio of the company is 1.7
- At the current price, the company has a high dividend yield of 0.6
4
Underperformed the market in the last 1 year
- The stock has generated a return of 2.73% in the last 1 year, much lower than market (China Shanghai Composite) returns of 15.18%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to PharmaBlock Sciences (Nanjing), Inc. should be less than 10%
- Overall Portfolio exposure to Miscellaneous should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Miscellaneous)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is PharmaBlock Sciences (Nanjing), Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
PharmaBlock Sciences (Nanjing), Inc.
2.57%
0.78
50.63%
China Shanghai Composite
14.77%
1.01
15.10%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
17.38%
EBIT Growth (5y)
4.40%
EBIT to Interest (avg)
36.57
Debt to EBITDA (avg)
1.36
Net Debt to Equity (avg)
0.16
Sales to Capital Employed (avg)
0.37
Tax Ratio
10.97%
Dividend Payout Ratio
25.37%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
12.85%
ROE (avg)
11.32%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
40
Industry P/E
Price to Book Value
2.12
EV to EBIT
36.03
EV to EBITDA
21.55
EV to Capital Employed
2.19
EV to Sales
4.06
PEG Ratio
1.72
Dividend Yield
0.61%
ROCE (Latest)
6.07%
ROE (Latest)
5.33%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend12What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CNY 669.66 MM
NET SALES(HY)
At CNY 908.41 MM has Grown at 23.77%
NET PROFIT(9M)
Higher at CNY 162.72 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -5.77 %
INVENTORY TURNOVER RATIO(HY)
Highest at 1.65%
DEBTORS TURNOVER RATIO(HY)
Highest at 5.18%
-4What is not working for the Company
ROCE(HY)
Lowest at 5.96%
RAW MATERIAL COST(Y)
Grown by 18.09% (YoY
NET PROFIT(Q)
At CNY 36.17 MM has Fallen at -29.7%
Here's what is working for PharmaBlock Sciences (Nanjing), Inc.
Net Sales
At CNY 908.41 MM has Grown at 23.77%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (CNY MM)
Operating Cash Flow
Highest at CNY 669.66 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CNY MM)
Debt-Equity Ratio
Lowest at -5.77 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Inventory Turnover Ratio
Highest at 1.65%
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 5.18%
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Here's what is not working for PharmaBlock Sciences (Nanjing), Inc.
Net Profit
At CNY 36.17 MM has Fallen at -29.7%
over average net sales of the previous four periods of CNY 51.45 MMMOJO Watch
Near term Net Profit trend is negative
Net Profit (CNY MM)
Raw Material Cost
Grown by 18.09% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
